Interview: Alnylam President On Patisiran Lift-Off Plans

 
• By Kevin Grogan

Barry Greene, president of Alnylam, tells Scrip that the company is happy to consider risk-sharing with payers, as the firm is confident about the 'extreme value' that its RNAi therapeutic for hATTR amyloidosis will offer, if approved.

Rocket
Alnylam is preparing for the launch of patisiran in mid-2018 • Source: Shutterstock

More from Business

More from Scrip